Skip to main content

Psoriatic Arthritis

Rheumatology Consultant
Lead author Lihi Eder, MD, PhD, answers our questions about her study that evaluated musculoskeletal issues preceding patients’ diagnosis of psoriatic arthritis. This period may represent a window for earlier diagnosis of PsA.
Rheumatology Consultant
Because scarce data exists on long-term treatment with biologic therapies in patients with psoriatic arthritis, the researchers in the FUTURE 2 study aimed to assess the 5-year results on the efficacy and safety of an interleukin-17A inhibitor.
Rheumatology Consultant
Rohan Machhar and Dafna D. Gladman, MD, from the Krembil Research Institute, answer our questions about their research on microRNA-21-5p as a potential biomarker to predict which patients with psoriasis will advance to psoriatic arthritis.
Rheumatology Consultant
Authors of a new study investigated the association between interleukin-31 and Th17 cytokine profile in the serum of patients with psoriatic arthritis. Learn about their findings here.
Rheumatology Consultant
The researchers sought to validate a cutoff value of the Psoriatic Arthritis Disease Activity Score that defines minimal disease activity state. They also aimed to validate previously defined PASDAS cutoffs for low and high disease activity.
Back to Top